Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bindeshwari Sinha

Internal Medicine Ocala, FL Medical Doctor

NPI 1760477277 CMS profile 1125179

1805 Se Lake Weir Ave, Ocala, FL 34471

Open in the dashboard

General payments

$6,939

259 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bindeshwari Sinha of Ocala, FL is reported in the CMS Open Payments database as having received $6,939 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 24
2024 General $990 38
2023 General $1,271 41
2022 General $725 32
2021 General $675 35
2020 General $776 51
2019 General $1,794 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bindeshwari Sinha
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bindeshwari Sinha were reported at $709. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bindeshwari Sinha Internal Medicine median Middle half National median
2019 $1,794 $159 $48–$570 $163
2020 $776 $119 $33–$402 $114
2021 $675 $135 $37–$521 $132
2022 $725 $141 $42–$496 $149
2023 $1,271 $149 $45–$519 $160
2024 $990 $154 $47–$537 $164
2025 $709 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,171 42 payments
  2. Amarin Pharma Inc. $813 42 payments
  3. Astellas Pharma US Inc $458 20 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $438 14 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $418 13 payments
  6. Novo Nordisk Inc $417 21 payments
  7. Ironwood Pharmaceuticals, Inc $396 4 payments
  8. Lilly USA, LLC $310 16 payments
  9. Amgen Inc. $295 10 payments
  10. GlaxoSmithKline, LLC. $275 14 payments
  11. Other $1,948 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,832 254 payments
  2. Education $103 4 payments
  3. Consulting Fee $5 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,000 36 payments
  2. LINZESS $792 8 payments
  3. Vascepa Cardiovascular $531 35 payments
  4. JARDIANCE Diabetes $391 12 payments
  5. Kerendia $293 12 payments
  6. Vascepa Hypertriglyceridemia $282 7 payments
  7. RYBELSUS $252 17 payments
  8. JARDIANCE Diabetes $244 12 payments
  9. Ozempic $236 16 payments
  10. Leqembi $234 4 payments
  11. Other $3,705 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 168 drugs

Part D claims

11,883

Median for Internal Medicine: 777

Drug cost

$1,185,944

Median for Internal Medicine: $73,373

Branded share of claims

19.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 117 $149,023
Eliquis Apixaban Brand 119 $144,386
Ozempic Semaglutide Brand 90 $144,333
Farxiga Dapagliflozin Propanediol Brand 74 $84,218
Januvia Sitagliptin Phosphate Brand 59 $77,156
Janumet Sitagliptin Phos/Metformin Hcl Brand 40 $50,993
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $47,352
Mounjaro Tirzepatide Brand 34 $45,525
Xarelto Rivaroxaban Brand 56 $33,874
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 24 $33,244

The 10 drugs with the highest cost, of 168 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$259,072

Of which drugs: $55

Medicare patients

542

Average age 77

Services billed

3,918

321 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 62%
Ischemic heart disease 52%
Arthritis 42%
Depression 38%
Atrial fibrillation 30%
COPD 30%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 35 60 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $162
$162 74 —
Wegovy
  • Novo Nordisk Inc $115
$115 — —
Veozah
  • Astellas Pharma US Inc $103
$103 — —
JARDIANCE
  • Lilly USA, LLC $65
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
$90 117 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record